Session Description:

Introducing our first Smart MDI system. It combines the power of real time CGM with predictive glucose alerts and the personalized insulin dosing to help your patients stay ahead of their glucose levels and take the right dose at the right time. Help your patients prevent highs and lows before they occur, while you can have access to your patients glucose and insulin data to help you optimize their glycemic control.

Session Description:

This Abbott symposium at ATTD 2022 will introduce you to the importance of personalized diabetes management and the human-empowering capability of diabetes technology. During this presentation, world-renowned diabetes experts will share professional insights into the different needs of patients for their glycemic management and into the importance of system affordability for patient empowerment. They will guide you through the relevance of Continuous Glucose Monitoring accuracy and performance in clinical decision making and will provide you with a clinical experience report on the FreeStyle Libre 3 system, our latest innovation in the FreeStyle Libre product portfolio. Our symposium will be completed with an engaging live Q&A session that will allow you to directly interact with the faculty and to ask questions. We look forward to welcoming you to this informative event!

Session Description:

Introducing new breakthroughs in diabetes technology from Dexcom, the leader in trusted CGM performance. We invite you to join us to learn more about the two newest additions to the Dexcom portfolio: Dexcom G7 and Dexcom ONE. This program will review current data on the use of RT-CGM for people with type 1 and type 2 diabetes, revealing opportunities to improve care across the lifespan. In this session you will gain a deeper understanding of the performance and accuracy of the Dexcom G7 System in both adult and pediatric populations and hear more about the unique features that can improve the efficiency and effectiveness of clinical decision making. We will share our strategy to expand access to CGM technology and increase utilization with Dexcom ONE globally. Additionally, our experts will share their practical experience for incorporating both products into your practice.

Session Description:

IIn this exciting 80-minute session chaired by Dr Julia Mader, the expert faculty will dive into how continuous glucose monitoring (CGM) and once-weekly insulins, treatment and technology united, can address current unmet needs in the management of type 2 diabetes (T2D). Professor Richard Bergenstal will start by discussing evidence and guidelines for use of CGM in clinical trials and day-to-day management of T2D. Dr Mader will introduce once-weekly insulins and present efficacy and safety data and post hoc CGM data from the insulin icodec Phase 2 trials. Finally, Dr Christophe De Block will put the data into clinical context by discussing how CGM and once-weekly insulins can impact future clinical trials, day-to-day clinical practice and patient management. Between plenary sessions, there will be interactive discussions between the experts about future perspectives, such as the insulin icodec Phase 3 programme ONWARDS, and the experts will answer audience questions. The symposium will take place on Thursday 28 April @ 16.40–18.00 CEST.